This site is intended for health professionals only

At the heart of general practice since 1960

Chlamydia screening: doubts on cost effectiveness

GP register-based population screening programmes for chlamydia infection are poor value for money, according to a new economic model.

GP register-based population screening programmes for chlamydia infection are poor value for money, according to a new economic model.

It would cost about £22,300 to prevent one major outcome ­ most commonly pelvic inflammatory disease leading to hospital admission
Having the disease would have to be equivalent to being in a state equivalent to death for nearly nine months for a GP register-based programme to meet NICE's cost-effectiveness threshold of £30,000 per QALY, said researchers from the universities of Birmingham and Bristol.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say